PURPOSE: Few biological prognosticators are useful for prediction of Richter syndrome (RS), representing the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma. Stereotyped B-cell receptors (BCR) may have prognostic effect in CLL progression. We tested the prognostic effect of stereotyped BCR for predicting RS transformation. EXPERIMENTAL DESIGN: The prevalence of stereotyped BCR was compared in RS (n = 69) versus nontransformed CLL (n = 714) by a case-control analysis. Subsequently, the effect of stereotyped BCR at CLL diagnosis on risk of RS transformation was actuarially assessed in a consecutive CLL series (n = 753). RESULTS: RS (n = 69) displayed a higher prevalence of stereotyped BCR (P < 0.001) compared with nontransformed CLL. The actuarial risk of RS transformation was significantly higher in CLL carrying stereotyped BCR (P < 0.001). Among BCR subsets most represented in CLL, subset 8 using IGHV4-39/IGHD6-13/IGHJ5 carried the highest risk of RS transformation [hazard ratio (HR), 24.50; P < 0.001]. Multivariate analysis selected stereotyped BCR (HR, 3.33; P = 0.001) and IGHV4-39 usage (HR, 4.03; P = 0.004) as independent predictors of RS transformation. The combination of IGHV4-39 usage and stereotyped BCR in the same patient identified CLL with a very high risk of RS transformation (5-year risk, 68.7%). The risk carried by stereotyped BCR and IGHV4-39 usage was specific for RS transformation and had no effect on CLL progression without transformation. CONCLUSIONS: Analysis of BCR features may help identify CLL patients at risk of RS. A close monitoring and a careful biopsy policy may help early recognition of RS in CLL patients using stereotyped BCR, particularly if combined with IGHV4-39.
PURPOSE: Few biological prognosticators are useful for prediction of Richter syndrome (RS), representing the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma. Stereotyped B-cell receptors (BCR) may have prognostic effect in CLL progression. We tested the prognostic effect of stereotyped BCR for predicting RS transformation. EXPERIMENTAL DESIGN: The prevalence of stereotyped BCR was compared in RS (n = 69) versus nontransformed CLL (n = 714) by a case-control analysis. Subsequently, the effect of stereotyped BCR at CLL diagnosis on risk of RS transformation was actuarially assessed in a consecutive CLL series (n = 753). RESULTS: RS (n = 69) displayed a higher prevalence of stereotyped BCR (P < 0.001) compared with nontransformed CLL. The actuarial risk of RS transformation was significantly higher in CLL carrying stereotyped BCR (P < 0.001). Among BCR subsets most represented in CLL, subset 8 using IGHV4-39/IGHD6-13/IGHJ5 carried the highest risk of RS transformation [hazard ratio (HR), 24.50; P < 0.001]. Multivariate analysis selected stereotyped BCR (HR, 3.33; P = 0.001) and IGHV4-39 usage (HR, 4.03; P = 0.004) as independent predictors of RS transformation. The combination of IGHV4-39 usage and stereotyped BCR in the same patient identified CLL with a very high risk of RS transformation (5-year risk, 68.7%). The risk carried by stereotyped BCR and IGHV4-39 usage was specific for RS transformation and had no effect on CLL progression without transformation. CONCLUSIONS: Analysis of BCR features may help identify CLL patients at risk of RS. A close monitoring and a careful biopsy policy may help early recognition of RS in CLL patients using stereotyped BCR, particularly if combined with IGHV4-39.
Authors: Jaime Imitola; Kelly Pitt; James L Peoples; Barbara Krynska; Hina Sheikh; Santosh Kesari; S Ausim Azizi Journal: J Neurooncol Date: 2012-05-10 Impact factor: 4.130
Authors: Elisa ten Hacken; Maria Gounari; Jaap Willem Back; Ekaterina Shimanovskaya; Lydia Scarfò; Ekaterina Kim; Jared Burks; Maurilio Ponzoni; Giuseppe Alvise Ramirez; William G Wierda; Zeev Estrov; Michael J Keating; Alessandra Ferrajoli; Kostas Stamatopoulos; Paolo Ghia; Jan A Burger Journal: Haematologica Date: 2017-07-27 Impact factor: 9.941
Authors: Lesley-Ann Sutton; Emma Young; Panagiotis Baliakas; Anastasia Hadzidimitriou; Theodoros Moysiadis; Karla Plevova; Davide Rossi; Jana Kminkova; Evangelia Stalika; Lone Bredo Pedersen; Jitka Malcikova; Andreas Agathangelidis; Zadie Davis; Larry Mansouri; Lydia Scarfò; Myriam Boudjoghra; Alba Navarro; Alice F Muggen; Xiao-Jie Yan; Florence Nguyen-Khac; Marta Larrayoz; Panagiotis Panagiotidis; Nicholas Chiorazzi; Carsten Utoft Niemann; Chrysoula Belessi; Elias Campo; Jonathan C Strefford; Anton W Langerak; David Oscier; Gianluca Gaidano; Sarka Pospisilova; Frederic Davi; Paolo Ghia; Kostas Stamatopoulos; Richard Rosenquist Journal: Haematologica Date: 2016-05-19 Impact factor: 9.941